Moderate Alzheimer Disease
Neurology
Prevalence
700.0 / 100K
Incidence
120.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| snk01 | NKGen Biotech, Inc. (NKGN) |
Frequently asked questions
How many drugs are in development for Moderate Alzheimer Disease?
BioSniper tracks 1 drug in development for Moderate Alzheimer Disease across 1 company.
How many clinical trials target Moderate Alzheimer Disease?
There are 1 clinical trial targeting Moderate Alzheimer Disease tracked by BioSniper.
What is the prevalence of Moderate Alzheimer Disease?
The estimated prevalence of Moderate Alzheimer Disease is approximately 700.0 per 100,000 population.
Deep-dive into Moderate Alzheimer Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis